{Reference Type}: Practice Guideline
{Title}: Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method.
{Author}: Sarradin V;Digue L;Vergez S;Thariat J;Fakhry N;Chabrillac E;Bensadoun RJ;Ferrand FR;Even C;
{Journal}: Eur Ann Otorhinolaryngol Head Neck Dis
{Volume}: 0
{Issue}: 0
{Year}: 2023 Nov 30
{Factor}: 2.665
{DOI}: 10.1016/j.anorl.2023.11.004
{Abstract}: <B>OBJECTIVE: </B>To determine the therapeutic indications for systemic medical treatment in the management of salivary gland carcinoma (excluding adenoid cystic carcinoma) according to the clinical situation.<BR><B>METHODS: </B>The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.<BR><B>RESULTS: </B>Salivary gland carcinoma is rare and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, initial management can be based on a phase of monitoring for indolent disease. Some histological subtypes (salivary duct carcinoma and adenocarcinoma) are more aggressive and require systemic treatment from the outset. To guide systemic treatment, it is recommended to perform immunohistochemistry and molecular biology analyses (overexpression of HER2 and androgen receptors, NTRK fusion, next-generation sequencing).<BR><B>CONCLUSIONS: </B>Salivary gland carcinoma is a rare tumor for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.